Directed Therapies in Lung Cancer: New Hope?

被引：3
|
作者：
Parente Lamelas, Isaura [1 ]
Abal Arca, Jose [1 ]
Firvida Perez, Jose Luis [2 ]
机构：
[1] Complexo Hosp Univ Ourense, Serv Neumol, Orense, Spain
[2] Complexo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain
来源：
ARCHIVOS DE BRONCONEUMOLOGIA | 2012年 / 48卷 / 10期
关键词：
Lung cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Anaplastic lymphoma kinase; Erlotinib; Gefitinib; Bevacizumab; Crizotinib; GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PHASE-III; OPEN-LABEL; 1ST-LINE THERAPY; GEFITINIB; MUTATIONS; SURVIVAL; ERLOTINIB; CHEMOTHERAPY;
D O I：
10.1016/j.arbres.2012.03.007
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK). (c) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：367 / 371
页数：5
相关论文
共 50 条
  • [11] EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
    de Mello, Ramon Andrade
    Liu, Davi J. J.
    Aguiar, Pedro N., Jr.
    Tadokoro, Hakaru
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (04) : 393 - 400
  • [12] Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: Targeted therapies in 2013
    Pecuchet, N.
    Bigot, F.
    Henni, M.
    Fabre, E.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2014, 70 (1-2) : 38 - 46
  • [13] Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
    Melosky, Barbara
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [14] Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer
    Losanno, Tania
    Gridelli, Cesare
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 837 - 851
  • [15] EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
    de Mello, Ramon Andrade
    Madureira, Pedro
    Carvalho, Liliana S.
    Araujo, Antonio
    O'Brien, Mary
    Popat, Sanjay
    PHARMACOGENOMICS, 2013, 14 (14) : 1765 - 1777
  • [16] Diacylglycerol kinase η modulates oncogenic properties of lung cancer cells
    Nakano, T.
    Iravani, A.
    Kim, M.
    Hozumi, Y.
    Lohse, M.
    Reichert, E.
    Crotty, T. M.
    Stafforini, D. M.
    Topham, M. K.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (01) : 29 - 35
  • [17] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [18] Maintenance therapies for non-small cell lung cancer
    Blais, Normand
    Kassouf, Elie
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [19] Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?
    Roeper, Julia
    Griesinger, Frank
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 1 - 7
  • [20] Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations
    Yokoyama, Yuhei
    Sonobe, Makoto
    Yamada, Tetsu
    Sato, Masaaki
    Menju, Toshi
    Aoyama, Akihiro
    Sato, Toshihiko
    Chen, Fengshi
    Omasa, Mitsugu
    Date, Hiroshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (06) : 1122 - 1129
12345